News Related to Neuroinflammatory Biomarkers

Related coverage linked through entity extraction aliases.

NeuroTherapia Completes Phase 2a Alzheimer's Trial with Positive Safety and Biomarker Results

Apr 07, 2026

NeuroTherapia has completed a Phase 2a trial of NTRX-07 in Alzheimer's patients, meeting safety objectives with no treatment-related serious adverse events. Preliminary biomarker analysis shows encouraging results, including MRI findings trending toward stabilization. The oral small molecule targets neuroinflammation and showed positive effects in animal models.

Arvinas Reports Phase 1 Data Showing ARV-102 Achieves Over 50% LRRK2 Degradation in Parkinson's

Mar 19, 2026

Arvinas announced phase 1 results for ARV-102, a PROTAC degrader that achieved more than 50% LRRK2 degradation in cerebrospinal fluid of Parkinson's patients after 28 days, with no serious adverse events reported.